Search research articles
Contact Us
Filters
Showing results (21-30 of 129) with videos related to
Page
of 13
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 17, 2008
Biomarkers in early clinical trials: the committed and the skeptics
Udai Banerji, Johann de Bono, Ian Judson, et al.
Molecular Cancer Research : MCR
|
February 27, 2020
Inactivation of <i>NF1</i> Promotes Resistance to EGFR Inhibition in <i>KRAS/NRAS/BRAF<sup>V600</sup></i> -Wild-Type Colorectal Cancer
Alexandros Georgiou, Adam Stewart, David Cunningham, et al.
British Journal of Cancer
|
July 22, 2016
Insights into significance of combined inhibition of MEK and m-TOR signalling output in KRAS mutant non-small-cell lung cancer
Sophie Broutin, Adam Stewart, Parames Thavasu, et al.
Cancer Treatment Reviews
|
December 4, 2012
Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions
David S Hong, Udai Banerji, Bahareh Tavana, et al.
Oncology
|
March 14, 2015
Percentage Change in Plasma Cytokeratin 18 Is Associated with Clinical Outcomes in Patients Receiving Pemetrexed and Carboplatin for the Adenocarcinoma Subtype of NSCLC
Alexios S Strimpakos, Udai Banerji, Parames Thavasu, et al.
Breast (Edinburgh, Scotland)
|
May 19, 2007
Factors determining outcome after third line chemotherapy for metastatic breast cancer
Udai Banerji, Alexandra Kuciejewska, Sue Ashley, et al.
Scientific Reports
|
February 19, 2020
The kinase polypharmacology landscape of clinical PARP inhibitors
Albert A Antolin, Malaka Ameratunga, Udai Banerji, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 6, 2005
Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models
Udai Banerji, Michael Walton, Florence Raynaud, et al.
BJC Reports
|
August 25, 2025
A retrospective study of the impact of comorbidity, polypharmacy and demographic factors on patient inclusion and healthcare delivery in phase I oncology trials
Hoda Nemat, Martin Orr, Lucy Barrow, et al.
Journal of Proteome Research
|
May 20, 2024
Secretome of Cancer-Associated Fibroblasts (CAFs) Influences Drug Sensitivity in Cancer Cells
Rachel Lau, Lu Yu, Theodoros I Roumeliotis, et al.
Page
of 13
Search research articles
Search
Showing results (21-30 of 129) with videos related to
Sort By:
Page
of 13
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 17, 2008
Biomarkers in early clinical trials: the committed and the skeptics
Udai Banerji, Johann de Bono, Ian Judson, et al.
Molecular Cancer Research : MCR
|
February 27, 2020
Inactivation of <i>NF1</i> Promotes Resistance to EGFR Inhibition in <i>KRAS/NRAS/BRAF<sup>V600</sup></i> -Wild-Type Colorectal Cancer
Alexandros Georgiou, Adam Stewart, David Cunningham, et al.
British Journal of Cancer
|
July 22, 2016
Insights into significance of combined inhibition of MEK and m-TOR signalling output in KRAS mutant non-small-cell lung cancer
Sophie Broutin, Adam Stewart, Parames Thavasu, et al.
Cancer Treatment Reviews
|
December 4, 2012
Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions
David S Hong, Udai Banerji, Bahareh Tavana, et al.
Oncology
|
March 14, 2015
Percentage Change in Plasma Cytokeratin 18 Is Associated with Clinical Outcomes in Patients Receiving Pemetrexed and Carboplatin for the Adenocarcinoma Subtype of NSCLC
Alexios S Strimpakos, Udai Banerji, Parames Thavasu, et al.
Breast (Edinburgh, Scotland)
|
May 19, 2007
Factors determining outcome after third line chemotherapy for metastatic breast cancer
Udai Banerji, Alexandra Kuciejewska, Sue Ashley, et al.
Scientific Reports
|
February 19, 2020
The kinase polypharmacology landscape of clinical PARP inhibitors
Albert A Antolin, Malaka Ameratunga, Udai Banerji, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 6, 2005
Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models
Udai Banerji, Michael Walton, Florence Raynaud, et al.
BJC Reports
|
August 25, 2025
A retrospective study of the impact of comorbidity, polypharmacy and demographic factors on patient inclusion and healthcare delivery in phase I oncology trials
Hoda Nemat, Martin Orr, Lucy Barrow, et al.
Journal of Proteome Research
|
May 20, 2024
Secretome of Cancer-Associated Fibroblasts (CAFs) Influences Drug Sensitivity in Cancer Cells
Rachel Lau, Lu Yu, Theodoros I Roumeliotis, et al.
Page
of 13